CCR4 and prostate carcinoma: Mogamulizumab reduced circulating CD4+Foxp3+ Tregs and CCR4+ Tregs but not CD8+ cytotoxic T cells and CD4+ helper T cells in dogs with prostate cancer (figure 3A).